Date:3/23/2010

equests, and are governed by strict compliance requirements. Prolifiq was recently selected one of America's Most Promising Companies by Forbes. Customers include: AtriCure, Cisco Systems, GE, The BBC, Associated Press, and Getty Images.

About AdvaMed (www.AdvaMed.org)

AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. Our members produce nearly 90 percent of the health care technology purchased annually in the United States and more than 50 percent purchased annually around the world. AdvaMed members range from the largest to the smallest medical technology innovators and companies.  For more information, visit www.advamed.org.

Legal Notice: All rights reserved. Prolifiq is either a t
'/>"/>

SOURCE Prolifiq Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Adnavance Technologies to Present Initial Data Supporting Direct Detection Molecular Diagnostic Tests at AdvaMed 2009 and BIOCOM Investor Conference
2. Medical Technology Executives Descend on D.C. as AdvaMed 2009: The MedTech Conference Kicks Off and Health Care Debate Continues
3. Vibrant Exhibit Hall Features Innovative Medical Technology at AdvaMed 2009
4. AdvaMed Releases New Survey Results on DTC Campaigns
5. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
6. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
7. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
8. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
9. Radius Selects First Preclinical Candidate From SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions
10. Sarah Cannon Research Institute Selects OmniComm Systems Electronic Data Capture Solution, TrialMaster(TM), for Clinical Trials Management
11. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target